Pharmaceutical - Pharmaceutical, North America, Ipsen


Regulatory briefs: Gilead files sofosbuvir; FDA approves Diclegis; Health Canada clears Dysport


US biotech firm Gilead Sciences (Nasdaq: GILD) says it has submitted a New Drug Application to the US…

Anti-viralsBiotechnologyDermatologicalsDiclegisDuchesnayDysportGilead SciencesIpsenNorth AmericaPharmaceuticalRegulationsofosbuvirValeant PharmaceuticalsWomen's Health

Regulatory briefs from Ipsen/Inspiration, Janssen and Astellas


French drugmaker Ipsen (Euronext: IPN) and partner USA-based privately-held Inspiration Biopharmaceuticals…

Astellas PharmaBiotechnologyEuropeInspiration BiopharmaceuticalsIpsenJanssen-CilagJohnson & JohnsonNorth AmericaOBI-1OncologyPharmaceuticalRegulationTarcevaZytiga

US FDA puts clinical hold on Ipsen and Inspiration's hemophilia drug candidate


There was bad news for French drugmaker Ipsen (Euronext: IPN) and partner privately-held US firm Inspiration…

IB1001Inspiration BiopharmaceuticalsIpsenNorth AmericaPharmaceuticalRegulationResearch

ThromboGenics re-files ocriplasmin BLA and Inspiration submits IB 1001 to FDA


Belgian biopharma company ThromboGenics NV (Euronext Brussels: THR) said this morning that it has resubmitted…

BiotechnologyInspiration BiopharmaceuticalsIpsenNorth AmericaocriplasminOphthalmicsPharmaceuticalRegulationThromboGenics

Ipsen invests $45 million in US R&D facility


French drugmaker Ipsen (Euronext: IPN) says its USA-based subsidiary, Biomeasure and its North American…

FinancialIpsenNorth AmericaPharmaceuticalResearch

Back to top